2026-Q1 MORGAN STANLEY 13F Filing: Morgan Stanley rotates into SPY, IWM while paring Alphabet bets

Morgan Stanley’s 2026-Q1 13F reveals a portfolio under aggressive reconstruction, deploying capital into a broad-market rally while actively rotating within its core mega-cap exposures. The filing shows a clear tactical pivot: adding heavily to broad ETFs and high-quality mega-cap laggards while trimming positions in names viewed as overheated.

• MSFT: Added aggressively despite a sharp decline in portfolio value; position weight moved from 3.50% to 2.79%.
• SPY: Massive tactical add of index exposure; portfolio weight rose from 1.19% to 1.59%.
• IWM: Russell 2000 exposure more than doubled; weight jumped from 0.25% to 0.44%.
• SMH: Semiconductor ETF heavily accumulated; weight increased from 0.06% to 0.13%.
• GOOGL & GOOG: Alphabet actively trimmed across both share classes; Class A moved from 2.28% to 2.10%, Class C from 1.35% to 1.24%.
• DASH: Shares were heavily sold down; weight contracted from 0.24% to 0.13%.
• AZN: Established a new position worth $1.37B, reaching a 0.08% weight.
• AZNN: Prior AstraZeneca ADR position was completely liquidated.
• LLY, TMO, UNH: All saw active trimming; LLY weight dropped to 0.86%, TMO to 0.32%, UNH to 0.24%.

The simultaneous accumulation of MSFT, TSLA, and AMZN while trimming GOOGL, GOOG, and DASH is a specific quality-tier swap within mega-cap tech. MSFT was the most aggressively added name by share count, with the firm absorbing the post-AI capex scare as a long-term entry point. The contrast with Alphabet’s trim is telling: Morgan Stanley is betting heavily that Microsoft’s enterprise moat holds up better than the advertising duopoly during this AI digestion phase.

The ETF activity is the real macro tell here. The firm layered into SPY (++$6.34B), IWM (++$3.17B), and SMH (++$1.14B) while trimming IVV. This is an active over-weighting of small-cap momentum and semiconductors relative to the cap-weighted S&P 500 that IVV purely tracks. The portfolio is taking on significant factor risk, betting that the Russell 2000 and the semiconductor cycle can outperform the broad index in the coming quarters, a bet reflected in the positive momentum tilt of the filing.

• Morgan Stanley rotated decisively within tech, buying the MSFT drawdown hard while trimming Alphabet and growth names like DASH and SHOP.
• The active ETF flows—swapping IVV for SPY, IWM, and SMH—signal a purposeful macro bet on small caps and semiconductors over a pure cap-weighted benchmark.
• A massive healthcare sector shakeout unfolded: traditional US names were trimmed to make room for a new $1.37B buy of AstraZeneca, alongside the complete liquidation of its prior ADR holding.